Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2

Bioorganic and Medicinal Chemistry Letters

Volumn 25, Issue 9, 2015, Pages 1884-1891

  Sifferlen, Thierry ^a   Boller, Amandine ^a   Chardonneau, Audrey ^a   Cottreel, Emmanuelle ^a   Gatfield, John ^a   Treiber, Alexander ^a   Roch, Catherine ^a   Jenck, Francois ^a   Aissaoui, Hamed ^a   Williams, Jodi T ^a   Brotschi, Christine ^a   Heidmann, Bibia ^a   Siegrist, Romain ^a   Boss, Christoph ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

CNS drug discovery; Dual orexin receptor antagonists; Metabolic stability; Orexin receptors; Selective orexin 2 receptor antagonists; Sleep

Indexed keywords

2 PYRROLIDONE DERIVATIVE; LACTAM; OREXIN RECEPTOR; OREXIN RECEPTOR ANTAGONIST;

ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; HUMAN; METABOLISM; ORAL DRUG ADMINISTRATION; RAT; SLEEP; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ADMINISTRATION, ORAL; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LACTAMS; MOLECULAR STRUCTURE; OREXIN RECEPTOR ANTAGONISTS; OREXIN RECEPTORS; PYRROLIDINONES; RATS; SLEEP; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84930928397     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2015.03.035     Document Type: Article

References (48)

1. L. de Lecea, T.S. Kilduff, C. Peyron, X.-B. Gao, P.E. Foye, P.E. Danielson, C. Fukuhara, E.L.F. Battenberg, V.T. Gautvik, F.S. Bartlett 2nd, W.N. Frankel, A.N. van den Pol, F.E. Bloom, K.M. Gautvik, and J.G. Sutcliffe Proc. Natl. Acad. Sci. U.S.A. 95 1998 322
2. T. Sakurai, A. Amemiya, M. Ishii, I. Matsuzaki, R.M. Chemelli, H. Tanaka, S.C. Williams, J.A. Richardson, G.P. Kozlowski, S. Wilson, J.R.S. Arch, R.E. Buckingham, A.C. Haynes, S.A. Carr, R.S. Annan, D.E. McNulty, W.-S. Liu, J.A. Terrett, N.A. Elshourbagy, D.J. Bergsma, and M. Yanagisawa Cell 92 1998 573
3. For recent reviews on the pharmacology of orexin receptors and the medicinal chemistry of orexin receptor antagonists: (a) J. Gatfield, C. Brisbare-Roch, F. Jenck, and C. Boss ChemMedChem 5 2010 1197
4. A.L. Gotter, A.L. Webber, P.J. Coleman, J.J. Renger, and C.J. Winrow Pharmacol. Rev. 64 2012 389
5. D. Hoyer, and L.H. Jacobson Neuropeptides 47 2013 477
6. T.-R. Xu, Y. Yang, R. Ward, L. Gao, and Y. Liu Cell. Signal. 25 2013 2413
7. C. Boss Expert Opin. Ther. Patents 24 2014 1367
8. J.A. Christopher Pharm. Pat. Anal. 3 2014 625
9. R. Koberstein, H. Aissaoui, D. Bur, M. Clozel, W. Fischli, F. Jenck, C. Mueller, O. Nayler, T. Sifferlen, A. Treiber, and T. Weller Chimia 57 2003 270
10. T. Sifferlen, C. Boss, E. Cottreel, R. Koberstein, M. Gude, H. Aissaoui, T. Weller, J. Gatfield, C. Brisbare-Roch, and F. Jenck Bioorg. Med. Chem. Lett. 20 2010 1539
11. T. Sifferlen, R. Koberstein, E. Cottreel, A. Boller, T. Weller, J. Gatfield, C. Brisbare-Roch, F. Jenck, and C. Boss Bioorg. Med. Chem. Lett. 23 2013 2212
12. T. Sifferlen, R. Koberstein, E. Cottreel, A. Boller, T. Weller, J. Gatfield, C. Brisbare-Roch, F. Jenck, and C. Boss Bioorg. Med. Chem. Lett. 23 2013 3857
13. 2R.
14. C. Brisbare-Roch, J. Dingemanse, R. Koberstein, P. Hoever, H. Aissaoui, S. Flores, C. Mueller, O. Nayler, J. van Gerven, S.L. de Haas, P. Hess, C. Qiu, S. Buchmann, M. Scherz, T. Weller, W. Fischli, M. Clozel, and F. Jenck Nat. Med. 13 2007 150
15. R. Di Fabio, A. Pellacani, S. Faedo, A. Roth, L. Piccoli, P. Gerrard, R.A. Porter, C.N. Johnson, K. Thewlis, D. Donati, L. Stasi, S. Spada, G. Stemp, D. Nash, C. Branch, L. Kindon, M. Massagrande, A. Poffe, S. Braggio, E. Chiarparin, C. Marchioro, E. Ratti, and M. Corsi Bioorg. Med. Chem. Lett. 21 2011 5562
16. C.D. Cox, M.J. Breslin, D.B. Whitman, J.D. Schreier, G.B. McGaughey, M.J. Bogusky, A.J. Roecker, S.P. Mercer, R.A. Bednar, W. Lemaire, J.G. Bruno, D.R. Reiss, C.M. Harrell, K.L. Murphy, S.L. Garson, S.M. Doran, T. Prueksaritanont, W.B. Anderson, C. Tang, S. Roller, T.D. Cabalu, D. Cui, G.D. Hartman, S.D. Young, K.S. Koblan, C.J. Winrow, J.J. Renger, and P.J. Coleman J. Med. Chem. 53 2010 5320
17. P.J. Coleman, J.D. Schreier, C.D. Cox, M.J. Breslin, D.B. Whitman, M.J. Bogusky, G.B. McGaughey, R.A. Bednar, W. Lemaire, S.M. Doran, S.V. Fox, S.L. Garson, A.L. Gotter, C.M. Harrell, D.R. Reiss, T.D. Cabalu, D. Cui, T. Prueksaritanont, J. Stevens, P.L. Tannenbaum, R.G. Ball, J. Stellabott, S.D. Young, G.D. Hartman, C.J. Winrow, and J.J. Renger ChemMedChem 7 2012 415
18. US Food and Drug Administration. FDA approves new type of sleep drug, Belsomra [media release]. August 13, 2014. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm409950.htm.
19. Selective orexin receptor antagonists have been recently reviewed: T.P. Lebold, P. Bonaventure, and B.T. Shireman Bioorg. Med. Chem. Lett. 23 2013 4761
20. C. Dugovic, J.E. Shelton, L.E. Aluisio, I.C. Fraser, X. Jiang, S.W. Sutton, P. Bonaventure, S. Yun, X. Li, B. Lord, C.A. Dvorak, N.I. Carruthers, and T.W. Lovenberg J. Pharmacol. Exp. Ther. 330 2009 142
21. For recent descriptions of 2-SORAs that demonstrated efficacy in preclinical sleep models: (a) A.J. Roecker, S.P. Mercer, J.D. Schreier, C.D. Cox, M.E. Fraley, J.T. Steen, W. Lemaire, J.G. Bruno, C.M. Harrell, S.L. Garson, A.L. Gotter, S.V. Fox, J. Stevens, P.L. Tannenbaum, T. Prueksaritanont, T.D. Cabalu, D. Cui, J. Stellabott, G.D. Hartman, S.D. Young, C.J. Winrow, J.J. Renger, and P.J. Coleman ChemMedChem 9 2014 311
22. C. Betschart, S. Hintermann, D. Behnke, S. Cotesta, M. Fendt, C.E. Gee, L.H. Jacobson, G. Laue, S. Ofner, V. Chaudhari, S. Badiger, C. Pandit, J. Wagner, and D. Hoyer J. Med. Chem. 56 2013 7590
23. A.J. Roecker, T.S. Reger, M.C. Mattern, S.P. Mercer, J.M. Bergman, J.D. Schreier, R.V. Cube, C.D. Cox, D. Li, W. Lemaire, J.G. Bruno, C.M. Harrell, S.L. Garson, A.L. Gotter, S.V. Fox, J. Stevens, P.L. Tannenbaum, T. Prueksaritanont, T.D. Cabalu, D. Cui, J. Stellabott, G.D. Hartman, S.D. Young, C.J. Winrow, J.J. Renger, and P.J. Coleman Bioorg. Med. Chem. Lett. 24 2014 4884
24. S.P. Mercer, A.J. Roecker, S. Garson, D.R. Reiss, C.M. Harrell, K.L. Murphy, J.G. Bruno, R.A. Bednar, W. Lemaire, D. Cui, T.D. Cabalu, C. Tang, T. Prueksaritanont, G.D. Hartman, S.D. Young, C.J. Winrow, J.J. Renger, and P.J. Coleman Bioorg. Med. Chem. Lett. 23 2013 6620
25. C. Boss, C. Roch-Brisbare, M.A. Steiner, A. Treiber, H. Dietrich, F. Jenck, M. von Raumer, T. Sifferlen, C. Brotschi, B. Heidmann, J.T. Williams, H. Aissaoui, R. Siegrist, and J. Gatfield ChemMedChem 9 2014 2486
26. T. Sifferlen, A. Boller, A. Chardonneau, E. Cottreel, J. Hoecker, H. Aissaoui, J.T. Williams, C. Brotschi, B. Heidmann, R. Siegrist, J. Gatfield, A. Treiber, C. Brisbare-Roch, F. Jenck, and C. Boss Bioorg. Med. Chem. Lett. 24 2014 1201
27. Our preliminary SAR studies in the lactam series have clarified the influence of the stereochemistry at C-5 on the orexin antagonistic activity. Thus, for racemic mixtures, only one enantiomer displayed useful levels of potency toward both orexin receptors.
28. int) for racemic mixtures and for the corresponding enantiopure compounds.
29. For a description of the synthesis of 2,3-dioxopyrrolidines via a multicomponent reaction, see: (a) J.R. Merchant, and V. Srinivasan Recl. Trav. Chim. Pays-Bas 81 1962 144
30. B. Metten, M. Kostermans, G. Van Baelen, M. Smet, and W. Dehaen Tetrahedron 62 2006 6018
31. A.P. Krapcho Synthesis 1982 805
32. The relative cis-configuration at the two stereogenic centers of 10 was unequivocally established by NOESY experiments. NOEs are observed from the proton of the CH(OH) group to the proton of the CH(aryl) moiety, indicating that the protons H-3 and H-5 are located at the same side of the five-membered ring. For diastereoselective reductions of related 5-arylpyrrolidine-2,3-diones, see: P. Camps, T. Gomez, D. Munoz-Torrero, J. Rull, L. Sanchez, F. Boschi, M. Comes-Franchini, A. Ricci, T. Calvet, M. Font-Bardia, E. De Clercq, and L. Naesens J. Org. Chem. 73 2008 6657
33. J.A. Dodge, J.I. Trujillo, and M. Presnell J. Org. Chem. 59 1994 234
34. DAST-mediated stereocontrolled fluorodehydroxylations of 3-hydroxypyrrolidin-2-ones are known to occur with inversion of stereochemistry: A.G. Avent, A.N. Bowler, P.M. Doyle, C.M. Marchand, and D.W. Young Tetrahedron Lett. 33 1992 1509
35. F.M. Cordero, F. Pisaneschi, K.M. Batista, S. Valenza, F. Machetti, and A. Brandi J. Org. Chem. 70 2005 856
36. B. Lal, B.N. Pramanik, M.S. Manhas, and A.K. Bose Tetrahedron Lett. 1977 1977 23
37. M. Vaultier, N. Knouzi, and R. Carrie Tetrahedron Lett. 24 1983 763
38. P. Camps, D. Munoz-Torrero, J. Rull, M. Font-Bardia, and X. Solans Tetrahedron: Asymmetry 18 2007 2947
39. S.E. Denmark, and R.Y. Baiazitov J. Org. Chem. 71 2006 593
40. T. Mase, I.N. Houpis, A. Akao, I. Dorziotis, K. Emerson, T. Hoang, T. Iida, T. Itoh, K. Kamei, S. Kato, Y. Kato, M. Kawasaki, F. Lang, J. Lee, J. Lynch, P. Maligres, A. Molina, T. Nemoto, S. Okada, R. Reamer, J.Z. Song, D. Tschaen, T. Wada, D. Zewge, R.P. Volante, P.J. Reider, and K. Tomimoto J. Org. Chem. 66 2001 6775
41. For a description, see Supporting information in Ref. 15.
42. The topological polar surface area (TPSA) and the calculated logarithm of partition coefficients between n-octanol and water (c Log P) were determined using ChemBioDraw Ultra (version 13.0) available from CambridgeSoft. TPSA as a surrogate measure of polarity and hydrogen bonding capacity is a key descriptor influencing brain penetration, and high TPSA values correlate with decreased passive permeability and/or increased P-glycoprotein-mediated efflux. Analyses of CNS drugs versus non-CNS drugs furnished useful guidelines for optimal TPSA with an accepted maximum value of 60-70 for favourable brain exposure: J. Kelder, P.D.J. Grootenhuis, D.M. Bayada, L.P.C. Delbressine, and J.-P. Ploemen Pharm. Res. 16 1999 1514
43. For a recent review on the use of α- and α,α-difluorinated carboxylic acid derivatives in chemical biology and drug discovery: T.L. March, M.R. Johnston, P.J. Duggan, and J. Gardiner Chem. Biodiversity 9 2012 2410
44. For a comprehensive review discussing the impact of hydrogen bonds on P-glycoprotein transport and permeability: P.V. Desai, T.J. Raub, and M.-J. Blanco Bioorg. Med. Chem. Lett. 22 2012 6540
45. For a description of the MDR1-MDCK permeability experiment: B. Feng, J.B. Mills, R.E. Davidson, R.J. Mireles, J.S. Janiszewski, M.D. Troutman, and S.M. de Morais Drug Metab. Dispos. 36 2008 268
46. A-to-B)] below 3.0 means low affinity of the compound for the human P-gp transporter system.
47. The absolute configuration at the two stereogenic centers of the enantiopure γ-lactam 46 was drawn arbitrarily.
48. Aissaoui, H.; Boss, C.; Brotschi, C.; Heidmann, B.; Sifferlen, T.; Williams, J. T. Patent WO2012/063207, 2012, Actelion Pharmaceuticals Ltd.